Recent developments in the implementation of novel designs for early-phase combination studies

Annals of Oncology

Volumn 26, Issue 5, 2015, Pages 1036-1037

  Wages, N A ^a   Conaway, M R ^a   Slingluff, C L ^b   Williams, M E ^a   Portell, C A ^a   Hwu, P ^c   Petroni, G R ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CLINICAL EFFECTIVENESS; DRUG INDUSTRY; DRUG SAFETY; FEASIBILITY STUDY; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; HIGH RISK PATIENT; HUMAN; IMMUNOGENICITY; LETTER; MANTLE CELL LYMPHOMA; MELANOMA; ONCOLOGY; PRIORITY JOURNAL; STUDY DESIGN; TREATMENT PLANNING; DRUG DESIGN; NEOPLASMS; PHASE 1 CLINICAL TRIAL (TOPIC);

ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE I AS TOPIC; DRUG DESIGN; HUMANS; MEDICAL ONCOLOGY; NEOPLASMS;

EID: 84929121372     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdv075     Document Type: Letter

References (5)

1. Riviere MK, Le Tourneau C, Paoletti X et al. Designs of drug-combination phase I trials in oncology: a systematic review of the literature. Ann Oncol 2015; 26: 669-674.
2. Wages NA, Conaway MR, O'Quigley J. Continual reassessment method for partial ordering. Biometrics 2011; 67: 1555-1563.
3. Wages NA, Conaway MR. Specifications of a continual reassessment method design for phase I trials of combined drugs. Pharm Stat 2013; 12: 217-224.
4. Wages NA, Slingluff CL, Petroni GR. A phase I/II adaptive design to determine the optimal treatment regimen from a set of combination immunotherapies in high-risk melanoma. Contemp Clin Trials 2015; 41: 172-179.
5. Wages NA, Conaway MR. Phase I/II adaptive design for drug combination oncology trials. Stat Med 2014; 33: 1990-2003.